Medizinische Universität Graz - Research portal
Selected Publication:
Spindler, M; Weilbach, F; Beer, M; Sandstede, J; Kostler, H; Strotmann, J; Voelker, WF; Hahn, D; Ertl, G; Gold, RF.
Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis
J Cardiovasc Pharmacol. 2003; 42(5):680-687
Doi: 10.1097/00005344-200311000-00015
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Beer Meinrad
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- As mitoxantrone is a recently approved immunosuppressant for managing multiple sclerosis, the number of patients treated with this effective but potentially cardiotoxic anthracenedione derivative will increase substantially. To detect subclinical mitoxantrone-induced cardiotoxicity, sensitive non-invasive diagnostic tools are required. Assuming that changes in myocardial high-energy phosphate metabolism and alterations in left ventricular (LV) diastolic performance might be early markers of mitoxantrone-induced cardiotoxicity we examined fifteen MS patients treated with mitoxantrone up to 100 mg/m2 compared with 15 matched control MS patients. 31P-magnetic resonance (MR) spectroscopy was employed to measure myocardial high-energy phosphate metabolism, MR imaging for morphometric evaluation of changes in LV geometry. Indices of diastolic performance were assessed by Doppler echocardiography. In this exploratory study, phosphocreatine/ATP ratios were comparable between mitoxantrone-treated and control patients (1.48 +/- 0.23 and 1.43 +/- 0.41). LV mass, LV end-diastolic and systolic volumes, wall motion score, EF and cardiac output did not differ between both groups. All parameters of diastolic performance (E/A-ratio, isovolumic relaxation time, and E-wave deceleration time) were not different and within normal limits.In conclusion, using advanced diagnostic methodology, including functional, morphometric, and biochemical measurements no cardiotoxic effect of mitoxantrone up to a cumulative dose range of 100 mg/m2 could be detected.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Case-Control Studies -
- Echocardiography, Doppler - methods
- Female -
- Heart - drug effects Heart - physiology Heart - radiography
- Humans -
- Magnetic Resonance Imaging - methods
- Male -
- Middle Aged -
- Mitoxantrone - therapeutic use Mitoxantrone - toxicity
- Multiple Sclerosis - drug therapy Multiple Sclerosis - metabolism Multiple Sclerosis - radiography
- Pilot Projects -
- Retrospective Studies -
- Statistics, Nonparametric -
- Ventricular Function, Left - drug effects Ventricular Function, Left - physiology
- Find related publications in this database (Keywords)
- cardiotoxicity
- echocardiography
- mitoxantrone
- MR spectroscopy
- multiple sclerosis